FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754249426> ?p ?o ?g. }

• W2754249426 abstract "Background ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept (ABA) in Canada and Europe (NCT02109666). Objectives To determine pt biologic (b)DMARD use prior to initiation and after discontinuation of ABA overall and by treatment line in ACTION. Methods Pts with RA initiated IV ABA as first- or second-/further-line therapy. Biologic-naive and biologic-failure pts were enrolled during three periods between May 2008 and December 2013. Pts could switch administration routes (IV to SC) during treatment. Crude retention rates (Kaplan–Meier) were compared by log-rank test. Results Of the 2364 pts enrolled, 2350 were evaluable for analysis: 673 (28.6%) were biologic naive and 1677 (71.4%) biologic failures. Baseline characteristics differed: biologic-failure pts had longer RA duration, higher CRP levels and prevalence of radiographic erosions, and lower rates of chronic obstructive pulmonary disease and neoplasms vs biologic-naive pts. Most biologic-failure pts (96.7%) had previously received ≥1 TNF inhibitor (TNFi): 48.7% had received 1 and 48.0% ≥2 TNFi; 56.6% had received ≥2 bDMARDs. The overall 2-year retention rate was 47.9% and was higher for biologic-naive vs biologic-failure pts (54.5 vs 45.2%; p 84 (IV) or >28 (SC) days, and thus were no longer temporary discontinuations, as predefined in the protocol. Three pts discontinued for bad compliance, 3 for lack of efficacy, 3 for remission/major improvement, 12 for safety and 15 for surgery. A good/moderate EULAR response was achieved by 76.7% of pts at the last follow-up before ABA discontinuation and 58.3% at ABA restart; mean (SD) DAS28 (CRP) was 3.2 (1.1) and 3.8 (1.4), respectively. Conclusions Prior to abatacept treatment, over half of biologic-failure pts had received ≥2 bDMARDs and most had received a TNFi. After initial discontinuation (protocol defined), over one-third of pts restarted abatacept. Disclosure of Interest R. Alten Grant/research support from: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, H.-M. Lorenz Consultant for: AbbVie, Bristol-Myers Squibb, Roche-Chugai, UCB, MSD, GSK, SOBI, Medac, Novartis, Janssen-Cilag, AstraZeneca, Pfizer, Actelion, Speakers bureau: AbbVie, Bristol-Myers Squibb, Roche-Chugai, UCB, MSD, GSK, SOBI, Medac, Novartis, Janssen-Cilag, AstraZeneca, Pfizer, Actelion, X. Mariette Grant/research support from: Biogen, Pfizer, UCB, Consultant for: Bristol-Myers Squibb, LFB, Pfizer, GSK, UCB, H. Nuslein Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, M. Galeazzi: None declared, F. Navarro Grant/research support from: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, Roche, Consultant for: Pfizer, MSD, Roche, UCB, AbbVie, Bristol-Myers Squibb, Jansen, Lilly, Speakers bureau: Pfizer, MSD, Roche, UCB, AbbVie, Bristol-Myers Squibb, M. Chartier Employee of: Bristol-Myers Squibb, Y. Elbez: None declared, C. Rauch Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, M. Le Bars Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb" @default.
• W2754249426 created "2017-09-25" @default.
• W2754249426 creator A5002428943 @default.
• W2754249426 creator A5003774188 @default.
• W2754249426 creator A5005291921 @default.
• W2754249426 creator A5015852574 @default.
• W2754249426 creator A5028181759 @default.
• W2754249426 creator A5044432396 @default.
• W2754249426 creator A5051196993 @default.
• W2754249426 creator A5060526475 @default.
• W2754249426 creator A5063037687 @default.
• W2754249426 creator A5084949464 @default.
• W2754249426 date "2017-06-01" @default.
• W2754249426 modified "2023-09-23" @default.
• W2754249426 title "AB0267 Treatment paradigms in real-world practice: biologic agent use prior to and after discontinuation of abatacept in the action study" @default.
• W2754249426 doi "https://doi.org/10.1136/annrheumdis-2017-eular.1392" @default.
• W2754249426 hasPublicationYear "2017" @default.
• W2754249426 type Work @default.
• W2754249426 sameAs 2754249426 @default.
• W2754249426 citedByCount "0" @default.
• W2754249426 crossrefType "proceedings-article" @default.
• W2754249426 hasAuthorship W2754249426A5002428943 @default.
• W2754249426 hasAuthorship W2754249426A5003774188 @default.
• W2754249426 hasAuthorship W2754249426A5005291921 @default.
• W2754249426 hasAuthorship W2754249426A5015852574 @default.
• W2754249426 hasAuthorship W2754249426A5028181759 @default.
• W2754249426 hasAuthorship W2754249426A5044432396 @default.
• W2754249426 hasAuthorship W2754249426A5051196993 @default.
• W2754249426 hasAuthorship W2754249426A5060526475 @default.
• W2754249426 hasAuthorship W2754249426A5063037687 @default.
• W2754249426 hasAuthorship W2754249426A5084949464 @default.
• W2754249426 hasBestOaLocation W27542494261 @default.
• W2754249426 hasConcept C126322002 @default.
• W2754249426 hasConcept C2777138892 @default.
• W2754249426 hasConcept C2777575956 @default.
• W2754249426 hasConcept C2778715236 @default.
• W2754249426 hasConcept C2779134260 @default.
• W2754249426 hasConcept C2779338263 @default.
• W2754249426 hasConcept C2779605438 @default.
• W2754249426 hasConcept C2779722408 @default.
• W2754249426 hasConcept C2780653079 @default.
• W2754249426 hasConcept C2911221801 @default.
• W2754249426 hasConcept C71924100 @default.
• W2754249426 hasConceptScore W2754249426C126322002 @default.
• W2754249426 hasConceptScore W2754249426C2777138892 @default.
• W2754249426 hasConceptScore W2754249426C2777575956 @default.
• W2754249426 hasConceptScore W2754249426C2778715236 @default.
• W2754249426 hasConceptScore W2754249426C2779134260 @default.
• W2754249426 hasConceptScore W2754249426C2779338263 @default.
• W2754249426 hasConceptScore W2754249426C2779605438 @default.
• W2754249426 hasConceptScore W2754249426C2779722408 @default.
• W2754249426 hasConceptScore W2754249426C2780653079 @default.
• W2754249426 hasConceptScore W2754249426C2911221801 @default.
• W2754249426 hasConceptScore W2754249426C71924100 @default.
• W2754249426 hasLocation W27542494261 @default.
• W2754249426 hasOpenAccess W2754249426 @default.
• W2754249426 hasPrimaryLocation W27542494261 @default.
• W2754249426 hasRelatedWork W2327097424 @default.
• W2754249426 hasRelatedWork W2331223991 @default.
• W2754249426 hasRelatedWork W2334356229 @default.
• W2754249426 hasRelatedWork W2410431210 @default.
• W2754249426 hasRelatedWork W2551636231 @default.
• W2754249426 hasRelatedWork W2552326957 @default.
• W2754249426 hasRelatedWork W2555402540 @default.
• W2754249426 hasRelatedWork W2557000498 @default.
• W2754249426 hasRelatedWork W2753248752 @default.
• W2754249426 hasRelatedWork W2754241019 @default.
• W2754249426 hasRelatedWork W2754803002 @default.
• W2754249426 hasRelatedWork W2755795982 @default.
• W2754249426 hasRelatedWork W2756015713 @default.
• W2754249426 hasRelatedWork W2808373473 @default.
• W2754249426 hasRelatedWork W2909246594 @default.
• W2754249426 hasRelatedWork W2951669248 @default.
• W2754249426 hasRelatedWork W3045160920 @default.
• W2754249426 hasRelatedWork W3097716538 @default.
• W2754249426 hasRelatedWork W3165462202 @default.
• W2754249426 hasRelatedWork W3165703708 @default.
• W2754249426 isParatext "false" @default.
• W2754249426 isRetracted "false" @default.
• W2754249426 magId "2754249426" @default.
• W2754249426 workType "article" @default.